BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. Onco Targets Ther 2020;13:7213-27. [PMID: 32801751 DOI: 10.2147/OTT.S246471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M, Li J, Lin W, Qi L, Yao C, Zheng Z, Chen C, Duan S, Qi Y. EPAS1 Promoter Hypermethylation is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer. Genet Test Mol Biomarkers 2022. [PMID: 35920832 DOI: 10.1089/gtmb.2021.0305] [Reference Citation Analysis]
2 Ran Q, Xu D, Wang Q, Wang D. Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA. Front Oncol 2022;12:835299. [DOI: 10.3389/fonc.2022.835299] [Reference Citation Analysis]
3 El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathol Res Pract 2022;233:153886. [PMID: 35405621 DOI: 10.1016/j.prp.2022.153886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Niu X, Wu T, Li G, Gu X, Tian Y, Cui H. Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance. Int J Biol Sci 2022;18:742-59. [PMID: 35002522 DOI: 10.7150/ijbs.68724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Rigalli JP, Theile D, Nilles J, Weiss J. Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning. Cells 2021;10:3137. [PMID: 34831358 DOI: 10.3390/cells10113137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
7 Hu X, Zhu H, Shen Y, Zhang X, He X, Xu X. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:696705. [PMID: 34367979 DOI: 10.3389/fonc.2021.696705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]